The risk for systemic vasculitides (SV) is increased among patients with tuberculosis (TB), especially among those with extrapulmonary disease, according to study findings published in Rheumatology.

Diabetes mellitus may lead to adverse outcomes in multidrug-resistant tuberculosis (MDR-TB) or DR-TB, according to systematic review and meta-analysis findings published in BMC Infectious Diseases.

Asylum seekers, refugees, those with HIV, incarcerated individuals, and homeless individuals often had TB prevalence ratios greater than 25 vs the general population.

Patients who use inhaled corticosteroids (ICS) to treat chronic obstructive pulmonary disease (COPD) have higher rates of tuberculosis and pneumonia than those who do not use ICS, according to study findings published in the International Journal of Chronic Obstructive Pulmonary Disease.

Among those with MDR-TB included in the meta-analysis, 27% showed resistance to fluoroquinolones and 11% showed resistance to second-line injectable drugs.

Patients with multidrug-resistant tuberculosis with a body mass index of less than 18.5kg/m2 had a 2.8-times higher odds of death.

Moxifloxacin, when used as part of a shorter treatment regimen for drug-resistant tuberculosis (DR-TB), appears not to increase the risk for prolonging the QT interval (ie, interval between heart contraction and relaxation — the Q through T waves seen on electrocardiogram). This was among study results recently published in the Journal of Clinical Tuberculosis and other Mycobacterial Diseases.

In high-income countries like Canada, patients with subclinical pulmonary tuberculosis (TB) are a heterogeneous group, accounting for one-fifth of all pulmonary TB culture-positive cases, according to findings published in Chest.